The use of Angiotensin converting enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARB) in COVID-19 Pandemic

Year 2020, Volume: 3 Issue: 1, 47 - 52, 30.04.2020

Özge Turgay Yıldırım

Abstract

The rapid and progressive spread of the new SARS coronavirus SARS-CoV-2 pandemic has significantly impacted the health of thousands of people, national health care systems and global economic stability. The characteristics of SARS-CoV-2 that distinguish this disease from influenza are higher transmission rates with higher risk of mortality than COVID-19, especially due to acute respiratory distress syndrome (ARDS).
The mechanism of the SARS-CoV-2 infection is the binding of the virus to the membrane-bound form of angiotensin converting enzyme 2 (ACE2), and the complex is taken up by the host cell. The assumption that ACE2 is the co-receptor of the coronavirus has led to the idea that the virus can be prevented from entering the cell by blocking or reducing its enzyme production. In addition, there are publications indicating; ACE inhibitors and angiotensin receptor blockers, which are drugs that are used frequently in patients with cardiovascular diseases and hypertension, increase ACE2 production. This has led to the discussion of the use of these drugs during COVID-19 infection. In this review, we aimed to discuss the relationship between ACE inhibitors, angiotensin receptor blockers and COVID-19.

Keywords

coronavirus, COVID-19, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, ACE2, SARS-CoV-2

COVID-19 Pandemisi, Anjiyotensin dönüştürücü enzim (ACE) inhibitörleri ve Anjiyotensin Resepör Blokörlerinin (ARB) kullanımı

Abstract

Yeni SARS koronavirüsü SARS-CoV-2 pandemisinin hızlı ve ilerici yayılması, binlerce kişinin sağlığını, ulusal sağlık bakım sistemlerini ve küresel ekonomik istikrarı önemli ölçüde etkilemiştir. SARS-CoV-2'nin bu hastalığı influenzadan ayıran özellikleri, özellikle akut solunum sıkıntısı sendromu (ARDS) nedeniyle COVID-19'dan daha yüksek mortalite riski ile birlikte daha yüksek bulaşma oranıdır
SARS-CoV-2 enfeksiyonu mekanizması, virüsün, anjiyotensin dönüştürücü enzim 2'nin (ACE2) membrana bağlı formuna bağlanması ve kompleksin konakçı hücre tarafından içeri alınmasıdır. ACE2'nin koronavirüsün koreseptörü olduğu kabulü, enzim bloke ederek veya yapımını azaltarak virüsün hücreye girişinin engellenebileceği fikrini ortaya çıkarmıştır. Bunun haricinde kardiyovasküler ve hipertansif hastalarda çok sık kullanılar ACE inhibitör ve anjiotensin reseptör blokörü olan ilaçların da ACE2 yapımını artırdığını beirten yayınlar mevcuttur. Bu durum da bu ilaçların COVID-19 enfeksiyonu sırasında kullanımını tartışmaya açmıştır. Bu derlemede ACE inhibitörleri, anjiotensin reseptör blokörleri ve COVID-19 ilişkisini tartışmayı amaçladık.

Keywords

coronavirüs, COVID-19, anjiyotensin reseptör blokörleri, ACE2, anjiyotensin dönüştürücü enzim inhibitörleri, SARS-CoV-2

References

• 1. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res 2011;81:85- 164.
• 2. Masters PS, Perlman S. Coronaviridae. In: Knipe DM, Howley PM, eds. Fields virology. 6th ed. Lippincott Williams & Wilkins, 2013:825-58.
• 3. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24:490-502.
• 4. Corman VM, Lienau J, Witzenrath M. [Coronaviruses as the cause of respiratory infections]. Internist (Berl.) 2019;60, 1136–1145
• 5. Fehr AR, Channappanavar R, Perlman S. Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. Annu. Rev. Med. 2017;68, 387–399.
• 6. Cameron MJ, Kelvin AA, Leon AJ. Lack of Innate Interferon Responses during SARS Coronavirus Infection in a Vaccination and Reinfection Ferret Model. Plos One, 7(9): e45842
• 7. de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14, 523–534.
• 8. Hoffmann M et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4. doi: 10.1016/j.cell.2020.02.052
• 9. Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. USA 2005;102, 14040–14045.
• 10. Li F, Li W, Farzan M, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science2005; 309, 1864–1868.
• 11. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302, 276–278
• 12. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
• 13. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395, 470–473.
• 14. Zhou P, Yang XL, Wang XG,, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7
• 15. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395, 514–523.
• 16. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382, 727–733
• 17. World Health Organisation (WHO). Available from: https://covid19.who.int/ Erişim tarihi: 17Nisan2020.
• 18. Matsuyama S, Nao N, Shirato K, et al . Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 2020:202002589; [Epub ahead of print]. 10.1073/pnas.2002589117 32165541
• 19. Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
• 20. Ferrario CM, Jessup J, Chappell MC. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005 May 24;111(20):2605-10.
• 21. Ishiyama Y, Gallagher P E, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004; 43(5), 970–976
• 22. Klimas J, Olvedy M, Ochodnicka-Mackovicova K, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. Journal of Cellular and Molecular Medicine. 2015; 19(8), 1965–1974. https://doi.org/10. 1111/jcmm.12573
• 23. Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. American Journal of Hypertension 2015; 28(1), 15–21. https://doi.org/10.1093/ajh/hpu086
• 24. Kuba K, Imai Y, Rao S, et al. "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury". Nature Medicine. 2005; 11 (8): 875–9. doi:10.1038/nm1267.
• 25. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005 Jul 7;436(7047):112-6.
• 26. Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xinxueguanbing Zazhi 2020 Mar 2;48:E004. https://doi.org/10.3760/cma.j.cn112148-20200220- 00105. 0
• 27. Henry C, Zaizafoun M, Stock E, et al. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. SAVE Proc 2018;31(4):419e23
• 28. de Simone G. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020. Available from: https://www. escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-theesc- council-on-hypertension-on-ace-inhibitors-and-ang Erişim tarihi: 18Nisan2020
• 29. Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19 Erişim tarihi: 18Nisan2020